Table 2 Sample characteristics
IA Patients (N = 125) | |
|---|---|
Age, years (mean, SD) | 62.7 (±12) |
Sex | |
Female | 75 (60%) |
Diagnosis | |
Rheumatoid arthritis | 111 (88.8%) |
Ankylosing Spondylitis | 4 (3.2%) |
Psoriatic Arthritis | 7 (5.6%) |
Other diagnoses | 3 (2.4%) |
Level of education | |
No or pre-primary education | 38 (30.6%) |
Primary education and lower secondary education | 42 (33.9%) |
Upper secondary education and tertiary education | 44 (35.5%) |
Disease duration, years (median, IQR) | 15 (7, 23) |
Pharmacotherapy | |
Methotrexate (subcutaneous) | 22 (17.6%) |
Methotrexate (oral) | 64 (51.2%) |
Leflunomide | 3 (2.4%) |
Hydroxychloroquine | 29 (23.2%) |
Sulfasalazine | 13 (10.4%) |
Gold (oral) | 1 (0.8%) |
Infliximab | 2 (1.6%) |
Etanercept | 15 (12%) |
Adalimumab | 7 (5.6%) |
Rituximab | 6 (4.8%) |
Abatacept | 5 (4%) |
Tocilizumab | 11 (8.8%) |